Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Other 2

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 51Carcinoma, Non-Small-Cell Lung 29Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 23Stomach Neoplasms 19Recurrence 19Multiple Myeloma 19Neoplasm Metastasis 18Carcinoma, Hepatocellular 17Lung Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 12Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 7

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Radiotherapy, Intensity-Modulated 11Paclitaxel 11Carboplatin 11Fluorouracil 10Biopsy 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Drug Therapy 9Taxes 7Surgical Procedures, Operative 7Celecoxib 7X-Rays 6Standard of Care 6Sentinel Lymph Node Biopsy 6Surveys and Questionnaires 5Nivolumab 5cemiplimab 4Metformin 4Fluorodeoxyglucose F18 4Docetaxel 4Chemoradiotherapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Mouth Neoplasms × Injections × Clear all
NCT05966194 2024-11-15

KEVLARx

EpicentRx, Inc.

Phase 2 Recruiting
216 enrolled
Head & NeckOther

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT03515538 2024-11-04

PREVLAR

EpicentRx, Inc.

Phase 2 Completed
53 enrolled 15 charts
Head & NeckOther

Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT04473716 2023-11-22

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Shanghai Jiao Tong University School of Medicine

Phase 1 Completed
20 enrolled
Head & Neck

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡